Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial

Table 3

SBP and DBP reductions (mm Hg) from baseline to Week 7 in overall patient population and different patient subgroups, based on the FAS.

	Adjusted mean SBP/DBP reduction from baseline		Adjusted mean treatment difference of T80/H25 versus T80 (95% CI)
	T80	T80/H25	SBP	DBP
Overall population	−28.5/−15.4	−37.0/−18.6	−8.5 (−10.6, −6.4)	−3.2 (−4.5, −1.9)
DM
Yes	−26.7/−17.2	−34.2/−18.6	−7.6 (−13.0, −2.2)	−1.5 (−4.8, 1.9)
No	−28.7/−15.1	−37.4/−18.6	−8.6 (−10.8, −6.4)	−3.4 (−4.8, −2.1)
eGFR category
<60 mL/min/1.73 m^2	−20.3/−13.3	−33.8/−17.0	−13.5 (−20.5, −6.5)	−3.7 ( −8.1, 0.6)
≥60 mL/min/1.73 m^2	−28.9/−15.5	−37.2/−18.7	−8.2 (−10.4, −6.1)	−3.2 (−4.5, −1.8)
BMI category
<25 kg/m^2	−30.1/−16.6	−36.0/−19.5	−5.9 (−10.0, −1.7)	−2.9 (−5.5, −0.3)
25–<30 kg/m^2	−28.9/−14.9	−37.5/−18.9	−8.6 (−11.7, −5.5)	−4.0 (−5.9, −2.1)
≥30 kg/m^2	−27.1/−15.2	−37.0/−17.8	−9.9 (−12.9, −6.8)	−2.6 (−4.6, −0.7)
10-year CHD risk category
CHD1 (risk < 10%)	−29.5/−15.7	−38.3/−19.1	−8.8 (−11.2, −6.3)	−3.4 (−4.9, −1.9)
CHD2 (risk ≥ 10–<20%)	−27.2/−14.9	−33.1/−17.3	−5.9 (−9.8, −2.0)	−2.4 (−4.8, 0.1)
CHD3 (risk ≥ 20%)	−25.3/−14.7	−32.9/−16.3	−7.7 (−14.0, −1.4)	−1.6 (−5.5, 2.3)
10-year CHD risk by tertiles
CHD risk tertile 1 (<3.62%)	−31.1/−17.9	−38.9/−19.6	−7.8 (−11.2, −4.5)	−1.7 (−3.8, 0.4)
CHD risk tertile 2 (≥3.62–<8.66%)	−27.4/−13.4	−37.7/−18.9	−10.3 (−13.8, −6.9)	−5.5 (−7.6, −3.3)
CHD risk tertile 3 (≥8.66%)	−27.2/−14.9	−33.9/−17.2	−6.7 (−9.9, −3.6)	−2.4 (−4.3, −0.4)

BMI: body mass index; CHD: coronary heart disease; CI: confidence interval; DBP: diastolic blood pressure; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; FAS: full analysis set; H25: hydrochlorothiazide 25 mg; SBP: systolic blood pressure; T80: telmisartan 80 mg.